Cargando…

Cross-clade neutralization of HIV-1 by a monoclonal antibody obtained by immunization with liposomes containing lipid A and a synthetic MPER peptide

Detalles Bibliográficos
Autores principales:	Matyas, GR, Jobe, O, Wieczorek, L, Peachman, KK, Beck, Z, Polonis, VR, Rao, M, Alving, CR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442087/ http://dx.doi.org/10.1186/1742-4690-9-S2-P4

Ejemplares similares

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

Neutralization and enhancement of trans infection by erythrocyte-bound HIV with antibodies and complement
por: Beck, Z, et al.
Publicado: (2012)

P04-22. Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1α and MIP-1β
por: Weaver, KL, et al.
Publicado: (2009)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

P12-08. Membrane-specific antibodies that simultaneously bind to gp41 of HIV-1 and membrane lipid epitopes are induced by immunization with liposomes
por: Beck, Z, et al.
Publicado: (2009)

Human Erythrocytes Selectively Bind and Enrich Infectious HIV-1 Virions
por: Beck, Zoltan, et al.
Publicado: (2009)

Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines
por: Matyas, Gary R., et al.
Publicado: (2010)

Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
por: Yi, Guohua, et al.
Publicado: (2013)

Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
por: Krebs, Shelly J., et al.
Publicado: (2014)

Refined identification of neutralization-resistant CRF02_AG viruses and their sensitivity to anti-MPER neutralizing antibodies
por: Jacob, RA, et al.
Publicado: (2012)

Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
por: Torres, Oscar B., et al.
Publicado: (2017)

Correction: Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
Publicado: (2015)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
por: Yi, Guohua, et al.
Publicado: (2013)

Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8
por: Soto, Cinque, et al.
Publicado: (2016)

An MPER antibody neutralizes HIV-1 using germline features shared among donors
por: Zhang, Lei, et al.
Publicado: (2019)

The impact of differences in viral entry and trafficking on the mechanism of HIV-1 neutralization
por: Cincotta, CD Macedo, et al.
Publicado: (2012)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro
por: van der Veen, Daan R, et al.
Publicado: (2008)

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12
por: Tumba, NL, et al.
Publicado: (2012)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies
por: Wiehe, K, et al.
Publicado: (2009)

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
por: Kim, Arthur S., et al.
Publicado: (2014)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21
por: Alving, Carl R., et al.
Publicado: (2023)

P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific
por: Wieczorek, L, et al.
Publicado: (2009)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

A comprehensive binding and neutralization analysis of plasma of HIV-1 subtype-C infected donors from India suggest MPER directed neutralization
por: Andrabi, R, et al.
Publicado: (2012)

Targeted modification of the Per2 clock gene alters circadian function in mPer2(luciferase) (mPer2(Luc)) mice
por: Ralph, Martin R., et al.
Publicado: (2021)

A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition
por: Lutje Hulsik, David, et al.
Publicado: (2013)

Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay
por: Rao, M, et al.
Publicado: (2012)

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 determinant for neutralization but not for antigen recognition
por: Weissenhorn, W, et al.
Publicado: (2012)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies
por: Rantalainen, Kimmo, et al.
Publicado: (2020)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

QS21-Initiated Fusion of Liposomal Small Unilamellar Vesicles to Form ALFQ Results in Concentration of Most of the Monophosphoryl Lipid A, QS21, and Cholesterol in Giant Unilamellar Vesicles
por: Abucayon, Erwin G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fa7502dqstissgho0iqro8blm7